Vevo F2 Imaging System
Archived on June 6, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 5:00 PM EDT
- Posted
- May 26, 2026
- Notice type
- Combined Synopsis/Solicitation
- Set-aside
- No Set aside used
- NAICS
- 334510: Electromedical and Electrotherapeutic Apparatus Manufacturing
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH NIAID
- Place of performance
- Bethesda, Maryland, 20892
- Last updated
- Oct 29, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- RFQ-NIAID-26-04446
- Notice ID
- 2064a5f8cff540ad93c2d061c5009368
Description
This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 “Streamlined Procedures for Evaluation and solicitation for commercial Items,” as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-26- 04446 and the solicitation is issued as a Request for Quotes (RFQ).
This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2024-05 dated May 22, 2024.
The North American Industry Classification System (NAICS) code for this procurement is 334510, Electromedical and Electrotherapeutic Apparatus Manufacturing, with a small business size standard of 1,250 employees. The requirement is being competed with a brand name restriction, and without a small business set-aside.
A high-resolution ultrasound imaging system is required to enable precise, real-time visualization of mouse embryos during in utero injection procedures. This capability is essential for accurate targeting of embryonic structures, improving procedural consistency, and increasing overall success rates. The system will support a range of applications including developmental biology studies, gene delivery, and disease modeling that depend on reliable embryonic manipulation.
Ultrasound guidance will reduce technical variability, minimize embryo loss, and allow confirmation of injection placement during procedures. The equipment is necessary to ensure efficient execution of ongoing and future research protocols that cannot be performed with sufficient accuracy using current methods.
NIH has a requirement for the following Brand Name Supplies:
Item(s) Serial/Product No. Quantity
Fujifilm Visualsonics Vevo Imaging System Vs -20076 - 1
3D Mode Software 12314 - 1
Power Dopler Mode 11952 - 1
Vevo Lab analysis software Vs20034 - 1
57 MHz transducer 53297 - 1
71 MHz transducer 53295 - 1
Vevo transducer port cover - 53709 - 1
Vevo Animal monitor Mouse platform - 53610 - 1
MX/UHFX series transducer array cover 51144 - 1
Vevo imaging Station 2 VS 20085 - 1
Vevo animal monitor Rat platform 53611 - 1
Vevo compat Dual Anesthesia System VS 12055 - 1
H Type regulator 10414 - 1
h type medical air regulator 11830 - 1
9 mm Bain Circuit 11486 - 1
Introductory 2 day training 12353 - 1
Vevo System installation 12370 - 1
Vevo standard protection service - 51263 - Qty 4
Shipping/Freight (if applicable)
Place of Performance: NIH, 9000 Rockville Pike, Building 10, Bethesda, MD 20892, United States. FOB: Destination
Delivery: Delivery estimate is 90 days after receipt and acceptance of award.
The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based on the following: technical capability to meet the requirements, price, and delivery.
By submitting a quote in response to this solicitation, vendor is accepting the following terms and conditions:
The following FAR provisions apply to this acquisition:
FAR 52.212-1 Instructions to Offerors Commercial Items (SEP 2023)
FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (MAY 2024)
FAR 52.204-7 System for Award Management (OCT 2018)
(Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure FAR 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record)
FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements – Representation (JAN 2017)
FAR 52.204–26 Covered Telecommunications Equipment or Services-Representation
(OCT 2020) *** Must complete representation if attached to this solicitation- see attachment 52.204-26
The following FAR contract clauses apply to this acquisition:
FAR 2.212-4 Contract Terms and Conditions Commercial Items (NOV 2023)
FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (MAR 2023)
FAR 52.204-13 System for Award Management Maintenance (OCT 2018)
FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (NOV 2021)
HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 2015)
FAR 52.252-2 -- Clauses Incorporated by Reference. (Feb 1998)
This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this address: http://farsite.hill.af.mil/vffara.htm
By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov).
Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov/far/loadmainre.html & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax.
Submission shall be received not later than June 5, 2026 @ 5:00 PM EST
Offers may be e-mailed to Linda Smith (linda.smith2@nih.gov) or Jessica Emerson at Jessica.emerson@nih.gov. Offers shall include RFQ number in the subject line (RFQ- NIAID-26- 04446). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f).
All responsible sources may submit an offer that will be considered by this Agency.
Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Jessica Emerson @ Jessica.emerson@nih.gov
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Files (4)
- Download
US SOW (1).docx
97 KBAdded in Combined Synopsis/Solicitation version 3Posted - Download
US SON (1).pdf
95 KBAdded in Combined Synopsis/Solicitation version 3Posted - Download
2_RFQ-NIAID-2604446.pdf
208 KBAdded in Combined Synopsis/Solicitation version 3Posted - Download
2_BOM_Ultrasound Machine.xlsx
12 KBAdded in Combined Synopsis/Solicitation version 3Posted
Lifecycle
- 3Version 3Combined Synopsis/SolicitationArchivedCurrent
Vevo F2 Imaging System
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Amendment 1 11/19/2026 Adds Response Form. No changes to response date. The Center for Biomedical Advanced Research and Development Authority (BARDA) intends to use responses to this Sources Sought Notice (SSN) for planning purposes. BARDA will not award any contracts under this Notice, but rather seeks current and forecasted prices, inventories, capabilities, and other pertinent marketplace data. This Notice is issued by the Center for Biomedical Advanced Research and Development Authority (BARDA) to identify innovative medical countermeasure technologies to enable rapid triage of musculoskeletal injuries such as fractures and soft tissue injuries of extremities. This request is for information only and is intended to assess the current state of commercially available technologies and technologies nearing commercial availability that support automated ultrasound-based fracture detection using technologies commonly known as Artificial Intelligence (AI). Consistent with Executive Order 14434, “Inaugurating the Era of Super Intelligence,” AI- technologies are now referred to as Super Intelligence (SI) throughout this notice, including in the title and should be referred the same in the response. The Center for Biomedical Advanced Research and Development Authority (BARDA) intends to use responses to this Sources Sought Notice (SSN) to inform planning for the potential acquisition of ultrasound-based devices capable of capturing and displaying anatomical data. Potential acquisition and inventory approaches include device purchases or leases supported by vendor-managed inventory (VMI) arrangements. BARDA seeks information on technologies that could assist clinical care providers in visualizing or detecting musculoskeletal injuries, including fractures and soft tissue injuries, to support triage and initial treatment in emergency departments, urgent care centers, and field settings. These devices could also support continued evaluation and treatment in definitive orthopedic care settings, consistent with applicable regulatory authorizations and intended uses. The U.S. Department of Health and Human Services (HHS) leads Federal public health and medical preparedness and response efforts, including supporting the research, development, acquisition, and availability of medical countermeasures (MCMs). These efforts address the health consequences of chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases, including threats arising from deliberate, accidental, or naturally occurring events. This SSN supports planning for medical capabilities that could strengthen the Nation’s preparedness for and response to emergencies involving traumatic injuries. The Project BioShield Act of 2004 (Pub. L. No. 108-276) established authorities for procuring qualifying security countermeasures for the Strategic National Stockpile (SNS). The Pandemic and All-Hazards Preparedness Act of 2006 (Pub. L. No. 109-417) further strengthened the Nation’s medical countermeasure development and preparedness framework. The National Health Security Strategy 2023–2026 provides additional strategic context for strengthening preparedness, response, and recovery capabilities. Consistent with these preparedness objectives, this Sources Sought Notice seeks information on potential approaches to improve the availability and accessibility of relevant medical devices across health care settings. Approaches of interest include purchase, lease, vendor-managed inventory (VMI), and arrangements that combine access to devices with maintenance and readiness support. Information received will inform acquisition planning and assessment of these approaches, subject to applicable statutory authorities, acquisition requirements, and availability of funds. These documents represent the foundation for addressing the Nation’s CBRN MCM needs. Amongst the foundational documents referenced above, musculoskeletal injuries such as fractures resulting from nuclear blast explosions and structural collapse, as well as and other mass casualty events present significant challenges in both field and clinical settings which require prompt diagnosis for adjudication and triage of patients. Current standards of care rely heavily on radiography and CT imaging, which are often unavailable, delayed, or resource-constrained in austere environments, disaster response settings, or during patient surge conditions. Delayed or missed fracture diagnosis can worsen patient outcomes and burden downstream care. BARDA is seeking solutions that enhance the speed, accuracy, and accessibility of fracture detection at the point of injury and point of care, without dependence on traditional imaging infrastructure. CAPABILITY STATEMENT/INFORMATION SOUGHT This Sources Sought Notice (SSN) seeks information from small business (SB) and other than small business (OTSB) concerns regarding their qualifications, experience, and capabilities to develop, manufacture, and deploy standalone, point-of-care, super intelligence (SI)-enabled ultrasound devices for fracture detection. Respondents shall provide only the information, data, and materials necessary to demonstrate their capabilities relevant to this notice. Responses shall include separate Technical Representation and Business Representation sections, as detailed below. Each section shall not exceed 10 single-sided pages, including all attachments, résumés, charts, and other supporting materials, and shall use 12-point Times New Roman font. Pages exceeding the limit for either section will not be reviewed. Respondents shall identify their business size status as either small business or other than small business under the NAICS code and corresponding size standard identified in this notice. Technical Representations Respondents shall provide the technical information requested by ASPR/BARDA in separately numbered sections, in the order listed below. For any section that does not apply, respondents shall retain the section number and heading, mark it “Not Applicable,” and briefly explain why it does not apply. Response Specification In response to this notice, clearly describe the capability and experience that meets the criteria specified in the subsequent categories. A template is provided for detailed and concise responses as related to the qualifying criteria. Additional supporting evidence, data, and information can be provided as attachments, not to exceed the 10-page limit per submission to this notice. All sponsors responding to this notice are required to provide the requested information on their products and capabilities by providing short responses, summarizing their device's diagnostic capability along with performance data, TRL and development status, regulatory documentation, product IFU, manufacturing overview, and supply-chain and production information. The narrative response to the templated prompts may include figures, schematics, diagrams, photographs, etc. and shall describe the proposed final product under consideration. Any proposed device must qualify against the following criteria (either work completed or demonstratable work in progress): Display and Diagnostic of Anatomy for Fracture Evaluation Capability Automated ultrasound imaging-based volumetric capture and display of detailed anatomy of different structures and providing bone detection/identification in areas such as wrist, ankles and others; and assist care providers to visualize clinically significant injuries such as fractures. Embedded ultrasound image processing information with appropriately trained Super Intelligence and machine learning (SI/ML) models to assist in image acquisition and segmentation for data interpretation with predefined sensitivity/specificity performance, which has been reviewed and adjudicated in FDA submissions for 510k clearance process. Models must be rigorously tested/validated against independent datasets separate from their training and their performance must improve upon that of human imaging experts. Capability either established or under development to distinguish different degrees / types of fracture and severity where it is deemed clinically appropriate, presence of edema or soft-tissue injuries. Capability to reconstruct and render 3D-rotatable models/ cross-sectional data review based on the captured ultrasound volumetric visualization of the bone and render the detection of injury and/or anatomy of the investigational areas for clinician adjudication. Use of color overlays for various anatomies and layers is ideal Performance comparison data against standard established technologies such as X-ray radiographic images or CT images. Desirable Device Design and Portability Characteristics Standalone, point-of-care form factor with integrated SI-processing. Units to be durable/ruggedized for field and disaster-response conditions Self-contained (e.g. all supplies and imaging media/gels sprays/wipes) all in a single portable unit which if required is field-deployable based on weight and size Battery life and power requirements suitable for use even under austere environments Ability to export and save data and link to EHR-systems within hospitals to enable billing and reimbursement. Interoperability with EHR or existing triage/documentation systems Use-Case Flexibility Operable in both field/austere environments and general clinical/hospital settings Minimal training burden for non-specialist operators (e.g., combat medics, first responders, general clinical technicians) Functions independently when a reliable network connectivity is unavailable Compatible with hospital ED workflows in rural and urban settings, use in urgent care centers and compatible with mass casualty triage workflows Development Status: Clinical and Regulatory Maturity Summary of advanced development pathway including various testing and validation performed; preclinical, clinical testing (MRMC, human factors) as well as bench testing. Regulatory Status: Pathway for product clearance/ approval as envisioned. Support this with a summary of pre-submission, FDA breakthrough designation efforts whether received or not, ongoing questions pending with FDA and/or feedback received. Any relevant work conducted under Department of War (DoW) or other federal agency Key technical risks identified, and mitigation plans Scalability and Manufacturing and Supply Chain Management / Resilience U.S. domestic maximum manufacturing capability and inventory management and warehousing strategy An established manufacturing process which covers required quality and ISO systems for GMP manufacture using reproducible, scalable processes with relevant operational certification from FDA and other regulatory bodies as a result of successful audits and accreditations. Strategy to establish supply chain resilience for all hardware and electronic components, sensors, transducers etc. critical for manufacture of the product. Cyber security and data storage and management security standards and certifications. List capability and testing for handling of sensitive patient PII and health information security and safeguards and transfer to other required systems such as electronic health records. Indicated Population and Use Cases Broad applicability across adult and pediatric patient populations Applicable to blast injuries, blunt trauma, structural collapse, and other mass casualty fracture presentations. Demonstrated or anticipated performance across a range of fracture types and anatomical locations. Response Format, Transmission, and Closing Date Respondents shall submit declarations of capability and all supporting information, data, and materials in Microsoft Office® or Adobe® Acrobat® format via email to Justin.Moore@hhs.gov and Richard.hall@hhs.gov. Responses must be received no later than 1:00 p.m. Eastern Time (ET) on November 18, 2026. All questions, comments, or concerns regarding this notice shall be submitted in writing to the same email address. | - | Market Research | 11/18/2026 |
Portfolio Acquisition Executive (PAE) Maneuver Ground Project Manager (PM) Maneuver Medical Devices (M2S) is issuing this Request for Prototype Proposals (RPP) under Other Transaction Authority (OTA) pursuant to 10 U.S.C. § 4022 to solicit prototype project proposals for a Scanner Ultrasonic Ocular device. The purpose of this RPP is to identify, select, and award two (2) prototype Other Transaction (OT) Agreement —for the delivery and demonstration of prototype scanner ultrasonic ocular devices that address the capability gap described herein. The awardee(s) shall deliver four (4) prototype devices for operational and environmental testing. The goal is to procure an FDA-approved commercial solution that requires minimal to no modifications to meet the technical specifications identified herein. | - | Combined Synopsis | 11/12/2026 |
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00038 /PCA-NIA-11810. This solicitation is issued as a competitive combined synopsis/solicitation for commercial products or commercial services. The Government intends to award a contract or purchase order resulting from this solicitation using full and open competition. This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. | - | Combined Synopsis | 12/08/2026 |
NON-COMPETITIVE COMBINED SYNOPSIS / SOLICITATION Title: Hidex 600SLe Liquid Scintillation Counter (i) This is a combined synopsis/solicitation for commercial products and commercial services prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00033 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial product or commercial service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; and FAR Part 12—Acquisition of Commercial Products and Commercial Services and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL AND OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH), Office of Acquisition and Logistics Management (OALM), on behalf of the NIH Office of Research Services (ORS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) for the purchase of a Hidex 600SLe Liquid Scintillation Counter. The anticipated award date is 10/30/2026. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2026-01, with effective date 03/13/2026. (iv) The associated NAICS code is 334516 and the small business size standard is 1000 employees. (v) The Contractor shall provide the following Hidex brand equipment: 600 SLe LSC with MikroWin. Catalog Number: AH-20XX-09. Quantity: 1. Alpha/Beta Separation for 300/600SL. Catalog Number: AH-NXX-04. Quantity: 1. Eu-152 External Standard. Catalog Number: AH-NXX-13. Quantity: 1. Windows 11 Desktop PC with Monitor. Catalog Number: P3G-36XX-01. Quantity: 1. Installation and Training. Catalog Number: GL-Z1XX-24. Quantity: 1. Shipping Contractor must also provide pricing for a trade-in discount. NIH will be trading in two old pieces of equipment in this acquisition. (vi) The Government anticipates award of a firm fixed-price purchase order for this acquisition, and the anticipated delivery date is 6-8 weeks ARO. (vii) The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html https://www.acquisition.gov/caac-letters (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (Nov 2024) FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) FAR 52.204-29, Federal Acquisition Supply Chain Security Act Orders – Representation and Disclosures (Dec 2023) FAR 52.212-1, Instructions to Offerors-Commercial Products and Commercial Services (Sep 2023) FAR 52.212-3, Offeror Representations and Certifications-Commercial Products and Commercial Services (May 2024) (DEVIATION Feb 2025) CAAC_Letter_2025-01_Supplement-1.pdf and CAAC_Letter_2025-02_Supplement-1.pdf FAR 52.222-52, Exemption from Application of the Service Contract Labor Standards to Contracts for Certain Services-Certification (May 2014) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html https://www.acquisition.gov/caac-letters (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (Oct 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020) FAR 52.212-4, Contract Terms and Conditions-Commercial Products and Commercial Services (Nov 2023). The following provisions and clauses apply to this acquisition and are attached in full text. Offerors MUST complete the provisions below and submit completed copies as separate documents with their proposal. FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Products and Commercial Services ( Jan 2025) (DEVIATION Feb 2025) Per CAAC Letters 2025-01 and 2025-02, FAR 52.222-21, Prohibition of Segregated Facilities and FAR 52.222-26 - Equal Opportunity will not be considered when making award decisions or enforce requirements. FAR 52.222-52 Exemption from Application of the Service Contract Labor Standards to Contracts for Certain Services-Certification (May 2014). HHSAR 352.239-78, Information and Communication Technology Accessibility Notice (Feb 2024) (DEVIATION). HHSAR 352.239-79, Information and Communication Technology Accessibility (Feb 2024) (DEVIATION). FAR DEVIATION STATEMENT: The CAAC Letter 2025-01 -Supplement 1 and CAAC Letter 2025-02-Supplement 1 are applicable to this acquisition. System updates may lag policy updates. The System for Award Management (SAM) may continue to require entities to complete representations based on provisions that are not included in agency solicitations. Examples include 52.222-25, Affirmative Action Compliance, and paragraph (d) of 52.212-3, Offeror Representations and Certifications—Commercial Products and Commercial Services. Contracting officers will not consider these representations when making award decisions or enforce requirements. Entities are not required to, nor are they able to, update their entity registration to remove these representations in SAM. The mentioned CAAC Letters may be accessed electronically at this address: CAAC Letters | Acquisition.GOV. The following invoice instruction is included and will be incorporated in the final award: NIH Invoicing Instructions with IPP (Mar 2023). (viii) The provision at FAR clause 52.212-2, Evaluation – Commercial Products and Commercial Services (Nov 2021), applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation is the lowest-priced technically-acceptable. (c) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer’s specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (ix) Offerors must include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Products and Commercial Services (May 2024) (DEVIATION Feb 2025), with its offer. If the offeror has completed FAR clause 52.212-3 at www.sam.gov, then the offeror does not need to provide a completed copy with its offer. See DEVIATION STATEMENT above regarding applicable CAAC Letters. (x) The following additional contract requirement(s) or terms and conditions as determined by the contracting officer are necessary for this acquisition and consistent with customary commercial practices. There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xi) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xii) Responses to this solicitation must include sufficient information to establish the interested parties’ bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s), product description, and any other information or factors that may be considered in the award decision. Such factors may include: past performance, special features required for effective program performance, trade-in considerations, probable life of the product selected as compared with that of a comparable product, warranty considerations, maintenance availability, and environmental and energy efficiency considerations. Responses to this solicitation must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement as it relates to the technical evaluation criteria. The price proposal must include the labor categories, an estimate of the number of hours required for each labor category, fully loaded fixed hourly rate or each labor category, breakdown and rationale for other direct costs or materials, and the total amount. The Unique Entity ID from SAM.gov, the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All quotations must be received by 12:00p.m., Eastern Standard Time, on October 29, 2026, and reference Solicitation Number 75N98027Q00033. Responses must be submitted electronically to Kevin Alvarez, Contracting Officer, kevin.alvarez@nih.gov. A determination by the Government whether to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered to determine whether to proceed on a non-competitive basis as indicated above, or to conduct a competitive procurement. Fax responses will not be accepted. | - | Special Notice | 10/29/2026 |
This is a combined synopsis/solicitation for commercial products prepared in accordance with the Revolutionary Federal Acquisition Regulation (FAR) Overhaul (RFO) Parts 12 and 15. This announcement constitutes the only solicitation. Offers are being requested and a separate written solicitation will not be issued. Solicitation number 36C10X27R0005 is issued as a Request for Proposal (RFP) for NX EQ Ultrasonic Aspirator System: Tissue Ablation and related accessories. This acquisition is set-aside for Service Disabled Veteran Owned Small Business (SDVOSB) concerns. This solicitation incorporates provisions and clauses by reference. The full text of provisions and clauses may be accessed electronically at www.acquisition.gov. Line Items: Refer to ATTACHMENT A PRICE COST SCHEDULE NX EQ Ultrasonic Aspirator System: Tissue Ablation for CLINs, quantities, and units of measure. Description of Requirements: Offerors shall provide descriptive literature which will be used to determine the extent to which it meets the salient characteristics listed in the Attachment B Product Description. All of the salient characteristics listed in the solicitation must be met to be considered eligible for award. Those proposals which fail to meet all of the salient characteristics will be rated Unacceptable and will be ineligible for award. Only new OEM equipment is acceptable. No refurbished, remanufactured, or gray market items will be considered. Delivery and Acceptance: Delivery is FOB Destination. Specific delivery locations and dates will be identified in individual orders issued under the contract. | - | Combined Synopsis | 12/01/2026 |
Additional Details
Solicitation Number
RFQ-NIAID-26-04446
Archive Date
Jun 6, 2026
Office Address
BETHESDA, MD, 20892